research use only
Cat.No.S8704
| Related Targets | JAK TGF-beta/Smad ERK GSK-3 ROCK Hedgehog/Smoothened PKA Secretase STAT Casein Kinase |
|---|---|
| Other Wnt/beta-catenin Inhibitors | IWR-1-endo PRI-724 (Foscenvivint) IWP-2 Tegatrabetan (BC-2059) Isoquercitrin ICG-001 SKL2001 BML-284 (Wnt agonist 1) PNU-74654 Salinomycin (Procoxacin) |
|
In vitro |
DMSO
: 37 mg/mL
(98.55 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 375.44 | Formula | C21H17N3O2S |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 677331-12-3 | -- | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | CC1=CC(=C(N1C2=CN=CC=C2)C)C=C3C(=O)N(C(=O)S3)C4=CC=CC=C4 | ||
| Targets/IC50/Ki |
β-catenin/Tcf
54 μM(Ki)
|
|---|---|
| In vitro |
iCRT14 suppresses the transcriptional activity of canonical Wnt signaling, downregulates Wnt/β-catenin-induced target genes, and inhibits the growth of colorectal cancer cells in vitro. This compound shows a modest reduction in the amount of Dvl but has no effect on Dvl phosphorylation itself. It inhibits the Wnt responsive STF16-luc reporter in mammalian HEK293 cells with an IC50 of 40.3 nM. This chemical can also interfere with TCF binding to DNA in addition to its ability to influence TCF-β-catenin interaction. |
| In vivo |
Administration of iCRT14 to the HCT116 and HT29 xenograft models reveals a marked decrease in CycD1, coincided with reduced proliferation of the tumors. Furthermore, these effects are correlated with a marked reduction (∼50%) in the initial growth rate of tumors within the first 3 wk (∼day 19) of this compound administration. After day 19, however, the rate of tumor growth is comparable with that of DMSO-treated control. Throughout the course of the study, the mice does not display any signs of systemic toxicity or weight loss that would indicate off-target or nonspecific effects. This compound may be metabolized rapidly in vivo, thus reducing its bioavailability. |
References |
|
| Methods | Biomarkers | Images | PMID |
|---|---|---|---|
| Western blot | BIRC5 / Myc / Axin2 caspase 3 / cleaved caspase 3 / cleaved PARP Snail / pS9-GSK-3β / GSK-3β / Akt1 / Akt2 |
|
24995804 |
| Growth inhibition assay | Cell viability |
|
24995804 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.